EUVIMEDEUVIMED entdecken
ValidierungsstudieOpen Access

Development and Validation of the RSClinN+ Tool to Predict Prognosis and Chemotherapy Benefit for Hormone Receptor–Positive, Node-Positive Breast Cancer

Lajos Pusztai iD, Jess R Hoag, Kathy S Albain iD, William E Barlow iD, Salomon M Stemmer, Allison Meisner, Gabriel N Hortobagyi iD, Steven Shak, James M Rae iD, Rick Baehner iD, Priyanka Sharma iD, Kevin M Kalinsky iD

Journal of Clinical Oncology · 10.03.2025 · 43 (8) · 919-928

DOI: 10.1200/jco-24-01507 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.03.2025. Verfasst von Lajos Pusztai und 11 weiteren Autor:innen. Beteiligte Einrichtung: Yale University School of Medicine, New Haven, CT. Hauptthemen laut MEDLINE: Breast Neoplasms. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Clinicopathological factors and the 21-gene Oncotype DX Breast Recurrence Score (RS) test both influence prognosis. Our goal was to develop a new tool, RSClinN+, to individualize recurrence risk and chemotherapy benefit predictions by menopausal status for patients with HR+/human epidermal growth factor receptor 2–negative, lymph node–positive breast cancer by integrating the RS result with clinicopathological factors (grade, tumor size, age). METHODS We used patient-level data from 5,283 patients treated with chemoendocrine therapy (CET) versus endocrine therapy alone (ET) in the S1007 (N = 4,916) and S8814 (N = 367) trials to develop the tool. Cox proportional hazards regression models stratified by trial were used to estimate 5-year invasive disease-free survival for pre- and postmenopausal woman, respectively. The integrated RSClinN+ model was compared with RS alone and clinicopathological models using likelihood ratio tests. Absolute CET benefit was estimated as the difference between ET and CET risk estimates. Validation of RSClinN+ was performed in 592 patients with node-positive disease in the Clalit Health Services registry. RESULTS RSClinN+ provides better prognostic information than RS model alone (premenopausal P = .034; postmenopausal P < .001) or clinicopathological model alone (premenopausal P = .002; postmenopausal, P < .001). In postmenopausal women, RS showed interaction with CET benefit ( P = .016), with RSClinN+ absolute CET benefit ranging from

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsHumansFemaleMiddle AgedReceptors, EstrogenPrognosisAdultErb-b2 Receptor Tyrosine KinasesAgedReceptors, ProgesteroneDisease-Free SurvivalLymphatic MetastasisNeoplasm Recurrence, LocalProportional Hazards ModelsBiomarkers, TumorAntineoplastic Agents, HormonalRisk Assessment

Substanzen

Receptors, EstrogenErb-b2 Receptor Tyrosine KinasesReceptors, ProgesteroneBiomarkers, TumorAntineoplastic Agents, HormonalERBB2 protein, human

Autor:innen und Institutionen

  • Yale University School of Medicine, New Haven, CT.
  • Exact Sciences Corporation, Madison, WI.
  • Loyola University Chicago Stritch School of Medicine, Maywood, IL.
  • SWOG Statistics and Data Management Center, Fred Hutchinson Cancer Center, Seattle, WA.
  • Tel Aviv University, Tel Aviv, Israel.
  • Rabin Medical Center, Petah Tikva, Israel.

ORCID-Profile: Lajos Pusztai, Kathy S Albain, William E Barlow, Gabriel N Hortobagyi, James M Rae, Rick Baehner, Priyanka Sharma, Kevin M Kalinsky

Förderung

  • NCI NIH HHS

Zitieren

APA

Pusztai, L., Hoag, J. R., Albain, K. S., Barlow, W. E., Stemmer, S. M., Meisner, A., Hortobagyi, G. N., Shak, S., Rae, J. M., Baehner, R., Sharma, P., & Kalinsky, K. M. (2025). Development and Validation of the RSClinN+ Tool to Predict Prognosis and Chemotherapy Benefit for Hormone Receptor–Positive, Node-Positive Breast Cancer. Journal of Clinical Oncology, 43(8), 919-928. https://doi.org/10.1200/jco-24-01507

Vancouver

Pusztai L, Hoag JR, Albain KS, Barlow WE, Stemmer SM, Meisner A, et al. Development and Validation of the RSClinN+ Tool to Predict Prognosis and Chemotherapy Benefit for Hormone Receptor–Positive, Node-Positive Breast Cancer. Journal of Clinical Oncology. 2025;43(8):919-928. doi:10.1200/jco-24-01507

BibTeX
@article{Pusztai2025,
  author = {Pusztai, Lajos and Hoag, Jess R and Albain, Kathy S and Barlow, William E and Stemmer, Salomon M and Meisner, Allison and Hortobagyi, Gabriel N and Shak, Steven and Rae, James M and Baehner, Rick and Sharma, Priyanka and Kalinsky, Kevin M},
  title = {Development and Validation of the RSClinN+ Tool to Predict Prognosis and Chemotherapy Benefit for Hormone Receptor–Positive, Node-Positive Breast Cancer},
  journal = {Journal of Clinical Oncology},
  year = {2025},
  volume = {43},
  number = {8},
  pages = {919--928},
  doi = {10.1200/jco-24-01507}
}
Kostenlos starten →